par Marechal, Raphaël
;De Schutter, Jef;Nagy, Nathalie
;Demetter, Pieter
;Lemmers, Arnaud
;Devière, Jacques
;Salmon, Isabelle
;Tejpar, Sabine;Van Laethem, Jean-Luc 
Référence BMC cancer, 10, page (340)
Publication Publié, 2010







Référence BMC cancer, 10, page (340)
Publication Publié, 2010
Article révisé par les pairs
Résumé : | Activity of cetuximab, a chimeric monoclonal antibody targeting the epidermal growth factor receptor, is largely attributed to its direct antiproliferative and proapoptotic effects. Antibody-dependent cell-mediated cytotoxicity (ADCC) could be another possible mechanism of cetuximab antitumor effects and its specific contribution on the clinical activity of cetuximab is unknown. |